Keith W. Roach, MD, is an associate professor of clinical medicine in the division of general medicine at NewYork-Presbyterian. Christopher Kelly, MD, from UNC Health, is a general cardiologist who ...

It’s common to wait until something feels “off” before making an appointment to see a healthcare provider. But waiting for noticeable symptoms can mean missing the chance to catch health issues early.

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

Primary care clinicians with higher diagnostic confidence are adopting emerging blood-based Alzheimer’s disease tests, ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Hims & Hers launched an artificial intelligence agent embedded in its platform to help interpret biomarker lab results and ...

Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers. Biomarker status has ...

Three years ago, New York state took a huge step forward by expanding access to biomarker testing, which is said to be a game changer in cancer care. Now, however, advocates fear the state could be ...